Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.59 |
| ▸ | MTOR | P42345 | 10/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.47 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114084 | 0.94 | PIK3CA (0.61) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL336204 | 0.90 | PIK3CA (0.67) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL337181 | 0.86 | PIK3CA (0.62) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL2877565 | 0.82 | PIK3CA (0.60) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1114137 | 0.81 | PIK3CA (0.59) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1114171 | 0.81 | PIK3CA (0.56) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1113658 | 0.80 | PIK3CA (0.57) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1113665 | 0.80 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL27813714 | 0.80 | PIK3CA (0.57) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1114001 | 0.80 | PIK3CA (0.72) | PIK3CAMTORPIK3CGPIK3R1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279188-B1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2279188-B1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-01-28 | — | — | EP | disclosed |
| CN-102105474-B | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2014-01-08 | — | — | CN | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2279188-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009146406-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 75/4885PIK3CG 3/4885 |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 75/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.